Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BCDA, unsubscribe in one click. Privacy
BCDA reported $4.1M in cash and short-term investments (as of Jun 30, 2026) and used about $1.7M/quarter in operations, an estimated runway of 7.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCDA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blank Andrew Scott | 5%+ holder (13D) | 278,253 | 1.84% | 2025-04-23 |
Share count 15,138,782 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCDA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →